Abstract
The pineal and retinal melatonin regulates endogenous circadian rhythms, and has various physiological functions including neuromodulatory and vasoactive actions, antioxidative and neuroprotective properties. We have previously demonstrated that the melatonin 1a-receptor (MT1) is localized in human retinal cells and that the expression of MT1 is increased in Alzheimer ’ s disease (AD) patients. We now present the first immunohistochemical evidence for the cellular distribution of the second melatonin receptor, MT2, in the human retina and in AD patients. In elderly controls, MT2 was localized to ganglion and bipolar cells in the inner nuclear layer, and to the inner segments of the photoreceptor cells. In addition, cellular processes in inner and outer plexiform layers were strongly positive for MT2. In AD patients the overall intensity of MT2-staining was distinctly decreased in all observed cellular localizations. Our results indicate that MT2 in the humans, similar to MT1, may indeed be involved in transmitting melatonin ’ s effects in the retina, and AD pathology may impair MT2 expression. Since our previous results showed an increase in MT1 expression in AD retina, the two melatonin receptor subtypes appear to be differentially affected by the course of the neurodegenerative disorder.
Keywords: Melatonin receptor, MT2, Retina, Alzheimer's disease
Current Alzheimer Research
Title: The MT2 Melatonin Receptor Subtype is Present in Human Retina and Decreases in Alzheimers Disease
Volume: 4 Issue: 1
Author(s): Egemen Savaskan, Ralf Jockers, Mohammed Ayoub, Debora Angeloni, Franco Fraschini, Josef Flammer, Anne Eckert, Franz Muller-Spahn and Peter Meyer
Affiliation:
Keywords: Melatonin receptor, MT2, Retina, Alzheimer's disease
Abstract: The pineal and retinal melatonin regulates endogenous circadian rhythms, and has various physiological functions including neuromodulatory and vasoactive actions, antioxidative and neuroprotective properties. We have previously demonstrated that the melatonin 1a-receptor (MT1) is localized in human retinal cells and that the expression of MT1 is increased in Alzheimer ’ s disease (AD) patients. We now present the first immunohistochemical evidence for the cellular distribution of the second melatonin receptor, MT2, in the human retina and in AD patients. In elderly controls, MT2 was localized to ganglion and bipolar cells in the inner nuclear layer, and to the inner segments of the photoreceptor cells. In addition, cellular processes in inner and outer plexiform layers were strongly positive for MT2. In AD patients the overall intensity of MT2-staining was distinctly decreased in all observed cellular localizations. Our results indicate that MT2 in the humans, similar to MT1, may indeed be involved in transmitting melatonin ’ s effects in the retina, and AD pathology may impair MT2 expression. Since our previous results showed an increase in MT1 expression in AD retina, the two melatonin receptor subtypes appear to be differentially affected by the course of the neurodegenerative disorder.
Export Options
About this article
Cite this article as:
Savaskan Egemen, Jockers Ralf, Ayoub Mohammed, Angeloni Debora, Fraschini Franco, Flammer Josef, Eckert Anne, Muller-Spahn Franz and Meyer Peter, The MT2 Melatonin Receptor Subtype is Present in Human Retina and Decreases in Alzheimers Disease, Current Alzheimer Research 2007; 4 (1) . https://dx.doi.org/10.2174/156720507779939823
DOI https://dx.doi.org/10.2174/156720507779939823 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Eluting Stents: Friend or Foe? A Review of Cellular Mechanisms Behind the Effects of Paclitaxel and Sirolimus Eluting Stents
Current Drug Metabolism Preservation Solutions for Solid Organ Transplantation
Mini-Reviews in Medicinal Chemistry Family B G Protein-coupled Receptors and their Ligands: From Structure to Function
Current Medicinal Chemistry Chondromodulin-I and Tenomodulin: The Negative Control of Angiogenesis in Connective Tissue
Current Pharmaceutical Design Perception of Symptoms in Hypertensive Patients and the Relevance to the Application of Anti- Hypertensive Drug Therapy
Current Pharmaceutical Design Novel Biomarkers Assessing the Calcium Deposition in Coronary Artery Disease
Current Medicinal Chemistry Harnessing CD36 to Rein in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Evolution of Exenatide as a Diabetes Therapeutic
Current Diabetes Reviews Patent Selections
Recent Patents on Cardiovascular Drug Discovery Adverse Drug Reactions of Acetaminophen and Ibuprofen in the Paediatric Population: Analysis of the Italian Spontaneous Reporting Database
Current Pediatric Reviews Old and New Drugs for Treatment of Stable Angina: New Anti-Anginal Drugs and Coronary Revascularization
Cardiovascular & Hematological Agents in Medicinal Chemistry Reactive Oxygen Species and Antioxidants in the Pathophysiology of Cardiovascular Disease: Does the Actual Knowledge Justify a Clinical Approach?
Current Vascular Pharmacology New Agents – Manifold Consequences: The Management of Lung and Colorectal Cancer is Changing
Current Cancer Therapy Reviews Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design Editorial [Hot Topic: Biochemical and Clinical Relevance of Hyperuricaemia (Executive Editor: Dimitri P. Mikhailidis Associate Editor: Stella S. Daskalopoulou)]
Current Pharmaceutical Design Current Landscape of Natural Products against Coronaviruses: Perspectives in COVID-19 Treatment and Anti-viral Mechanism
Current Pharmaceutical Design Preparation, Characterization, and In Vitro Release of Vinorelbine Tartrate (VLBT)- Loaded Folate-conjugated Recombination Human Serum Albumin (rHSA) Nanoparticles with Different Degree of Cross-linking
Current Nanoscience The Opioid Receptor Independent Actions of Kappa Receptor Agonists in the Cardiovascular System
Current Pharmaceutical Design Roles of Orexins and Orexin Receptors in Central Regulation of Feeding Behavior and Energy Homeostasis
CNS & Neurological Disorders - Drug Targets The Roles of Cytochrome P450 in Ischemic Heart Disease
Current Drug Metabolism